Related Experiment Video
Updated: Apr 26, 2026
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
Published on: April 25, 2022
MicroRNA dysregulation in the myelodysplastic syndromes
Stephen S Chung, Christopher Y Park1
11275 York Avenue, Box 20, New York, NY 10065, USA.
Abstract:
The myelodysplastic syndromes (MDS) are heterogeneous clonal disorders of ineffective hematopoiesis characterized by limited treatment options and a poor prognosis. These poor clinical characteristics stem from a poor understanding of the molecular abnormalities that drive disease pathogenesis. MicroRNAs (miRNAs) have recently been described to play wide-ranging roles in normal and malignant hematopoiesis, but very few miRNAs have been shown to be consistently dysregulated in MDS. Even fewer candidate disease miRNAs have undergone functional validation, and the clinical relevance of these miRNAs remains to be determined. Despite the fact that MDS has been shown to be a disease initiated in hematopoietic stem cells (HSC), most existing studies examining miRNA expression in MDS have used unfractionated or only partially purified bone marrow (BM) cell populations, likely explaining in part the limited insight that provided by these studies. A more robust characterization of purified disease -initiating cell populations followed by rigorous functional validation using in vivo disease models will be vital to identifying dysregulated miRNAs of functional significance in MDS. Such studies promise to provide key insights into disease pathogenesis and potentially open new avenues towards the development of therapies targeting miRNAs themselves or the pathways that they regulate.
Insights
Myelodysplastic syndromes (MDS) are poorly understood blood disorders. Research highlights the need to study microRNAs (miRNAs) in hematopoietic stem cells for new MDS therapies.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Myelodysplastic syndromes (MDS) are heterogeneous clonal disorders of ineffective hematopoiesis.
- Limited understanding of molecular drivers and few validated microRNAs (miRNAs) contribute to poor prognosis in MDS.
- Previous studies using unfractionated bone marrow limit insight into miRNA dysregulation in disease-initiating cells.
Purpose of the Study:
- To investigate the role of microRNAs (miRNAs) in the pathogenesis of myelodysplastic syndromes (MDS).
- To identify functionally significant dysregulated miRNAs in purified hematopoietic stem cells (HSCs) in MDS.
- To explore novel therapeutic strategies targeting miRNAs or their regulated pathways in MDS.
Main Methods:
- Characterization of miRNA expression in purified hematopoietic stem cells (HSCs) from MDS patients.
- Functional validation of candidate miRNAs using in vivo disease models.
- Analysis of miRNA dysregulation in the context of MDS pathogenesis.
Main Results:
- Few miRNAs are consistently dysregulated in MDS, and fewer have undergone functional validation.
- Studies on unfractionated bone marrow cells limit understanding of miRNA roles in MDS-initiating cells.
- Robust characterization of purified HSCs and functional validation are crucial for identifying significant miRNAs.
Conclusions:
- Identifying dysregulated miRNAs in purified MDS stem cells is vital for understanding disease pathogenesis.
- Functional validation in vivo is essential to determine the clinical relevance of candidate miRNAs.
- Targeting miRNAs or their pathways may offer new therapeutic avenues for MDS.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
01:22MicroRNAs
02:23Abnormal Proliferation
02:23Master Transcription Regulators